A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

PHASE2CompletedINTERVENTIONAL
Enrollment

792

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

April 4, 2016

Study Completion Date

April 4, 2016

Conditions
Influenza
Interventions
BIOLOGICAL

High-dose quadrivalent influenza virus vaccine

0.5 mL, Intramuscular (IM), injected into the deltoid area

BIOLOGICAL

High-dose influenza virus vaccine

0.5 mL, Intramuscular (IM), injected into the deltoid area

BIOLOGICAL

High-dose trivalent inactivated influenza vaccine

0.5 mL, Intramuscular (IM), injected into the deltoid area

BIOLOGICAL

High-dose trivalent inactivated influenza vaccine

0.5 mL, Intramuscular (IM), injected into the deltoid area

Trial Locations (9)

14609

Rochester

33134

Coral Gables

37212

Nashville

63104

St Louis

67207

Wichita

84088

West Jordan

84109

Salt Lake City

06460

Milford

02886

Warwick

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02553343 - A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older | Biotech Hunter | Biotech Hunter